Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431348 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4431395 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4431257 | 0.99 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4422424 | 0.96 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4426333 | 0.96 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4419067 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4432971 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4421537 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL4428834 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 | |
| SCHEMBL8343332 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | claimed |
| US-7544675-B2 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2009-06-09 | — | — | US | claimed |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | claimed |
| EP-1499598-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003087064-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2003-10-23 | — | — | WO | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1499598-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087064-A1 | CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | UCB, S.A. (BE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | PDE7A, CHRM3, PDE4B | PDE4A 5/4885PDE4B 3/4885PDE4C 12/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | PDE4A 1001/4885PDE4B 959/4885PDE4C 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.